Tell the PCAC to Approve the Bulk Ingredient Nominations!

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) will meet on March 8 and 9 to discuss whether to allow a new group of substances to be compounded. Substances under consideration include boswellia (an anti-inflammatory that can be used to treat arthritis and osteoarthritis), aloe vera (treats everything from burns to constipation, psoriasis, and herpes simplex virus), d-ribose (increases energy production and can rejuvenate heart muscles after a heart attack), chondroitin sulfate (stimulates the production of cartilage, improves blood circulation to the joints, and treats osteoarthritis), and acetyl-L-carnitine, an antioxidant that is used for Alzheimer’s and age-related memory problems).

These are commonly available supplements, yet the committee seems to think that everyday supplements should be banned from compounding. This is completely illogical. Send a message to the PCAC urging them to approve the ingredients that have been nominated to the Bulk Ingredient List—and send a copy to Congress as well. Your legislators need to see what is happening to their compounding law!

 

Please personalize and add your own
comments if you have time!

Recipients

  • Your Senators
  • Your Representative
  • Pharmacy Compounding Advisory Committee

Contact

*Required fields
 
 

Message

Please Approve the Compounding Bulk Ingredient Nominations

Dear [Decision Maker],

Sincerely,
[Your Name]
[Your Address]
[City, State ZIP]